Targets › TNFRSF9
7 programs from 7 companies in 11 trials: 7 Phase 2, 2 Phase 3, 2 Phase 1; Oncology; next expected readout Dec 2026.
Receptor for TNFSF9/4-1BBL. Conveys a signal that enhances CD8(+) T-cell survival, cytotoxicity, and mitochondrial activity, thereby promoting immunity against viruses and tumors (Probable). (UniProt, Q07011)
Open in Phaseline: the race on TNFRSF9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | Utomilumab Tumor necrosis factor receptor superfamily member 9 agonist | TNFRSF9 | Phase 3 | Advanced Malignancies; Stage III Breast Cancer; Breast Cancer; Advanced Malignant Solid Neoplasm | Dec 2026 |
| Genmab | Acasunlimab Bispecific antibody that engages PD-L1 and 4-1BB | CD274, TNFRSF9 | Phase 3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Jul 2027 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Urelumab Tumor necrosis factor receptor superfamily member 9 agonist | TNFRSF9 | Phase 2 | Pancreatic Cancer; Urothelial Carcinoma | Dec 2026 |
| Lyvgen Biopharma Holdings | LVGN6051 4-1BB agonistic antibody | TNFRSF9 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oct 2027 |
| Fudan University | SHR-1701 4-1BB agonist monoclonal antibody | TNFRSF9 | Phase 2 | Prostate Cancer | Mar 2028 |
| Pieris Pharmaceuticals | Cinrebafusp alfa (PRS-343) HER2/4-1BB bispecific antibody | ERBB2, TNFRSF9 | Phase 2 | HER2-positive Gastric Cancer | – |
| Bangdong Gong | iC9/CAR19/IL15 CB-NK cell Chimeric Antigen Receptor Natural Killer Cell targeting CD19 with inducible suicide gene ( | TNFRSF9, CD19, IL15 | Phase 1 | Primary Sjogren's Syndrome | Oct 2027 |
Advanced Malignancies (1) Stage III Breast Cancer (1) Breast Cancer (1) Advanced Malignant Solid Neoplasm (1) Head and Neck Squamous Cell Carcinoma (1) Primary Sjogren's Syndrome (1) Pancreatic Cancer (1) Urothelial Carcinoma (1) PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC (1) HER2-positive Gastric Cancer (1) Prostate Cancer (1)
mixed (4), other (1), antibody (1), small molecule (1)
Pfizer (1) Lyvgen Biopharma Holdings (1) Bangdong Gong (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) Genmab (1) Pieris Pharmaceuticals (1) Fudan University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.